Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Supplemental Cash Flow Information

12 Months Ended

Dec. 31, 2017

19.

Supplemental Cash Flow Information

	For The Years Ended December 31,
	2017			2016
Net cash used in operating activities of discontinued operations	$	(2,291	)	$	(2,000	)

Net cash provided by investing activities of discontinued operations	$	-		$	-

Supplemental Disclosures of Non Cash Financing Activities

(in thousands)

	Years Ended December 31,
	2017			2016
Investing
Acquisition of property and equipment	$	54		$	-
Tenant incentives recorded as part of deferred rent	$	84		$	-

Financing

Settlement of the RedPath Note ⁽¹⁾	$	(8,098	)	$	-
Issuance of the Exchange Notes ⁽¹⁾	$	11,375		$	-
Common shares issued in debt exchange (3,795,429 shares)	$	11,643		$	-

⁽¹⁾ Excludes approximately $732 of transaction fees which are included in loss on extinguishment of debt.